The Use of Synthetic Peptides in the Formation of Biophysically and Biologically Active Pulmonary Surfactants

  title={The Use of Synthetic Peptides in the Formation of Biophysically and Biologically Active Pulmonary Surfactants},
  author={Susan D. Revak and Thurman Allen Merritt and Mikko Hallman and Gregory P. Heldt and Robert J La Polla and Kenway Hoey and Richard A. Houghten and Charles G. Cochrane},
  journal={Pediatric Research},
ABSTRACT: Synthetic pulmonary surfactants consisting of mixtures of phospholipids with synthetic peptides based on the amino acid sequence of human surfactant apoprotein SP-B were prepared. These surfactants were analyzed for their ability to lower surface tension on a pulsating bubble surfactometer and for their capacity to improve lung compliance and increase alveolar expansion in a fetal rabbit model of surfactant deficiency. The data demonstrate that several peptides, ranging from 17 to 45… 

Figures and Tables from this paper

Synthetic mimics of surfactant proteins B and C: in vitro surface activity and effects on lung compliance in two animal models of surfactant deficiency.

In vitro functional determinations of synthetic surfactant peptides are instrumental in the preparation of replacement surfactants, and that dispersions thus selected represent viable therapeutic alternatives to current treatments for respiratory distress syndrome.

Synthetic Surfactant Protein Analogues

The inferior in vivo activity of synthetic surfactants containing SP-C only compared to that of surfactant preparations derived from natural sources may be caused by a lack of covalently linked palmitoyl groups in the analogues and/or absence of SP-B.

Protein-phospholipid interactions in pulmonary surfactant. The Parker B. Francis Lectureship.

Simplified peptide analogues of SP-B, dispersed in DPPC and POPG, provide strong surfactant activity in vitro and in the lungs of premature infant rabbits, rhesus monkeys, and humans.

Advances in synthetic lung surfactant protein technology

Second generation synthetic lung surfactants are created, using advanced SP-B and SP-C peptide mimics, to boost survival and decreased morbidity of preterm infants born at the margins of viability.

Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits.

It is suggested that a combination of synthetic surfactant peptides B1-78 and C1-35 and the clinical surfactants Survanta confer a high degree of resistance to surfactan inhibition by human albumin in ventilated preterm rabbits.

Efficacy of Synthetic Peptide-Containing Surfactant in the Treatment of Respiratory Distress Syndrome in Preterm Infant Rhesus Monkeys

The importance of the peptide in the synthetic surfactant was apparent, and animals treated with a dose of 200 mg/kg showed a faster, more consistent, and greater response than did a group treated with an average dose of 127mg/kg.

Design of Surfactant Protein B Peptide Mimics Based on the Saposin Fold for Synthetic Lung Surfactants

Based on the known 3D-structural motif for the saposin family, it is shown how bioengineering techniques may be used to develop minimal peptide constructs that maintain desirable structural properties and activities in biomedical applications.



Synthetic amphipathic sequences of surfactant protein-B mimic several physicochemical and in vivo properties of native pulmonary surfactant proteins.

A mixture of lipids and proteins unique to the lung lines the airspaces of all mammalian species. This mixture, termed pulmonary surfactant, is essential for normal lung function. We have synthesized

Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity.

The ability to produce biologically active surfactant by the addition of isolated LMW apoproteins to defined PL is shown.

Proteolipid in bovine lung surfactant: its role in surfactant function.

Reconstitution of surfactant activity using purified human apoprotein and phospholipids measured in vitro and in vivo.

The surfactant produced by recombination of the phospholipids with the isolated apoprotein was, therefore, shown to be biophysically active both in vitro and in vivo.

Reconstitution of surfactant activity by using the 6 kDa apoprotein associated with pulmonary surfactant.

Results indicate that the presence of the 6 kDa apoprotein can account for some of the essential physical and biological characteristics of pulmonary surfactant.

Hydrophobic Surfactant-Associated Protein in Whole Lung Surfactant and Its Importance for Biophysical Activity in Lung Surfactant Extracts Used for Replacement Therapy

Low molecular weight, hydrophobic, surfactant- associated protein, SAP 6-14, was distinguished from SAP-35, the major glycoprotein in mammalian surfactants by amino acid composition, peptide mapping, and by resistance of SAP-14 to digestion by endoglycosidase F, collagenase, trypsin, and other proteases.

Low molecular weight human pulmonary surfactant protein (SP5): isolation, characterization, and cDNA and amino acid sequences.

A hydrophobic surfactant protein of approximately 5 kDa is purified from bronchopulmonary lavage fluid from a patient with alveolar proteinosis and it is shown that it promotes rapid surface film formation by simple mixtures of phospholipids.

The role of the low-molecular weight (less than or equal to 15,000 daltons) apoproteins of pulmonary surfactant.

Systematic studies should be undertaken to find out whether an even more effective artificial surfactant could be prepared from the low-molecular weight apoproteins and other combinations of synthetic phospholipids.